A research project at Ghent University developing microbiome-assisted plant tissue culture methods. By introducing specific bacterial endophytes into in vitro plant cell cultures, researchers aim to manipulate metabolic pathways and enhance the production of high-value secondary metabolites in medicinal plants.
Microbiome-assisted plant tissue culture is a research initiative investigating the use of endophytic bacteria to manipulate plant growth and secondary metabolism under in vitro conditions. By leveraging the symbiotic relationship between plants and specific bacteria, this research seeks to move beyond traditional sterilization approaches, instead using controlled microbial inoculants to stimulate the production of high-value phytochemicals in medicinal plants. The approach offers potential for optimizing plant cell suspension cultures for industrial and pharmaceutical applications.
The technology is currently in the development phase, with research validated at the laboratory scale. Studies have successfully demonstrated the isolation of endophytes and the efficacy of co-culture techniques in modifying the metabolic profiles of medicinal plants like Alkanna tinctoria, with researchers actively publishing findings and pursuing further experimental development. It is classified at TRL 4 (component and/or breadboard validation in laboratory environment).
Ghent University is a comprehensive public research university with a strong applied research and innovation culture. Industry collaborates through the Tech Lane Ghent Science Park, where corporate R&D, public research institutes and UGent labs are co‑located, and via a second science park in Ostend. Integration with Ghent University Hospital enables clinical translation and access to patient care environments. Research is backed by competitive European programmes such as Horizon Europe and the ERC, alongside national and regional support from FWO and VLAIO. UGent’s TechTransfer office, working with an Industrial Liaison Network and a central EU funding team, supports IP, licensing, spin‑offs and contract research to accelerate partnerships.